A new community-based pickleball program called Project Rally is helping cancer survivors improve their physical and social well-being, according to a recent pilot study led by researchers at Moffitt Cancer Center. The program, which is offered in partnership with the YMCA of the Suncoast, has shown strong results in terms of participation, enjoyment, and physical improvements.
A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer Research, found that measuring the interaction between two proteins, RAS and RAF, could provide valuable insights into the effectiveness of treatments for patients with KRASG12C-mutant non-small cell lung cancer, a type of lung cancer known for being particularly difficult to treat.
A new study led by researchers from Moffitt Cancer Center, in collaboration with investigators from the University of Michigan, shows that artificial intelligence (AI) can help doctors make better decisions when treating cancer. However, it also highlights challenges in how doctors and AI work together. The study, published in Nature Communications, focused on AI-assisted radiotherapy for non-small cell lung cancer and hepatocellular carcinoma (liver cancer).
A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed. The study, published in Neuro-Oncology, suggests that doctors may need to rethink current screening guidelines for detecting brain metastasis in patients without symptoms.
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests 鈥� Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris 鈥� can help doctors make better decisions about how to treat patients with early stage prostate cancer. The review, published in the Annals of Internal Medicine, shows that these tests can provide more detailed information about the cancer, but experts say more data is needed on the cost-effectiveness and clinical utility of these tests, as well as their impact on racial and ethnic groups, especially Black men.
Tiffany Carson, Ph.D., co-leader of Health Outcomes and Behavior Program at Moffitt Cancer Center, has been elected as a Fellow in the Academy of Behavioral Medicine Research (ABMR), recognizing her outstanding contributions to the field of behavioral medicine.
A new study has uncovered an unexpected way cancer cells can escape the immune system, making it harder for treatments to work. The study, published in Cancer Cell, explains how a type of cancer cell death can actually make tumors grow faster by turning off the immune system鈥檚 ability to fight the cancer.
A new study has found a surprising link between high levels of methylmalonic acid and the weakening of CD8+ T cells, shedding light on potential pathways through which aging may promote lung cancer progression. Moffitt Cancer Center researchers have found new insights into how metabolic changes associated with aging can impact immune responses against tumors.
A new study has unveiled crucial information about the incidence and risk factors of oral human papillomavirus (HPV) infections among men in the United States, Mexico and Brazil. Moffitt Cancer Center researchers have discovered how often new oral HPV infections occur, the factors influencing their acquisition and the regional variations in infection rates.
TAMPA, Fla. - A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment. Led by a team of researchers at Moffitt Cancer Center, this comprehensive analysis represents a significant advancement in the understanding of these unique immune cells and their implications for patient outcomes in cancer therapy.
Immune checkpoint inhibitors are a type of cancer treatment that helps the immune system attack cancer cells more effectively. One of the key proteins involved in this process is Lymphocyte Activation Gene-3 (LAG3), which suppresses the antitumor immune response.
Moffitt Cancer Center researchers have developed a novel reagent that enhances the precision of drug synthesis. This innovative method, published in Nature Communications, introduces a new sulfur fluoride exchange (SuFEx) reagent that allows for highly controlled production of crucial sulfur-based molecules, including sulfinamides, sulfonimidamides and sulfoximines.
Axicabtagene ciloleucel, commonly known as axi-cel, is an innovative immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleucel has been a game-changer in treating large B-cell lymphoma.
In a new study published in npj Complexity, Moffitt Cancer Center researchers offer a new perspective on antifragility, proposing a unified framework for understanding the property across different complex systems.
A new study published today in Cancer Discovery is providing insights into why some Merkel cell carcinoma patients respond to this type of immunotherapy while others do not.
In a new commentary published in Cancer Cell, Moffitt Cancer Center scientists provide a comprehensive overview of the therapy鈥檚 development and highlight its transformative potential.
Moffitt Cancer Center researchers have developed a groundbreaking method for the scalable synthesis of withanolides.
A new study led by researchers at Moffitt Cancer Center introduces an adaptive therapy approach that could optimize PARP inhibitor maintenance therapy, offering a more personalized and potentially less toxic treatment option for patients. Their work is featured as the cover article of the June 19 issue of Cell Systems.
Leptomeningeal disease is a rare but lethal complication faced by late-stage melanoma patients. It occurs when cancer cells spread to the membranes covering the brain and spinal cord, or the leptomeninges. This condition, which affects 5% to 8% of melanoma patients, often leads to rapid deterioration and is notoriously resistant to therapies. However, a new Moffitt Cancer Center study, published today in Cell Reports Medicine, uncovers the mechanisms that drive this drug resistance, offering new avenues for potential treatments.
Bioengineering is revolutionizing cancer research, and Moffitt Cancer Center is at the forefront of this transformative movement. Moffitt is the first National Cancer Institute-designated comprehensive cancer center with a dedicated bioengineering department. This area of science integrates engineering and physical sciences with oncology to change how we understand and treat this complex disease.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 海角社区 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right